Table 3. Outcomes by Quartile of Baseline Risk for Moderate or Severe NDI or Death Between Birth and Follow-up.
| Outcome | Treatment group, No./total No. (%) | Relative risk (95% CI) | Risk difference (95% CI) | |
|---|---|---|---|---|
| Hydrocortisone | Placebo | |||
| Moderate or severe NDI or death by follow-up | ||||
| Quartile 1 | 56/97 (57.7) | 42/76 (55.3) | 1.04 (0.80 to 1.36) | 0.02 (−0.12 to 0.17) |
| Quartile 2 | 53/80 (66.3) | 64/101 (63.4) | 1.05 (0.84 to 1.30) | 0.03 (−0.11 to 0.17) |
| Quartile 3 | 57/90 (63.3) | 59/92 (64.1) | 0.99 (0.79 to 1.23) | −0.01 (−0.15 to 0.13) |
| Quartile 4 | 60/91 (65.9) | 60/90 (66.7) | 0.99 (0.80 to 1.22) | −0.01 (−0.15 to 0.13) |
| Overall | 226/358 (63.1) | 225/359 (62.7) | 1.01 (0.90 to 1.13) | 0.00 (−0.07 to 0.08) |
| Moderate or severe NDI | ||||
| Quartile 1 | 51/92 (55.4) | 40/74 (54.1) | 1.03 (0.78 to 1.36) | 0.01 (−0.14 to 0.17) |
| Quartile 2 | 48/75 (64.0) | 57/94 (60.6) | 1.06 (0.83 to 1.34) | 0.03 (−0.11 to 0.18) |
| Quartile 3 | 45/78 (57.7) | 42/75 (56.0) | 1.03 (0.78 to 1.36) | 0.02 (−0.14 to 0.17) |
| Quartile 4 | 39/70 (55.7) | 40/70 (57.1) | 0.98 (0.73 to 1.30) | −0.01 (−0.18 to 0.15) |
| Overall | 183/315 (58.1) | 179/313 (57.2) | 1.02 (0.89 to 1.16) | 0.01 (−0.07 to 0.09) |
| Death by follow-up | ||||
| Quartile 1 | 5/95 (5.3) | 2/73 (2.7) | 1.92 (0.38 to 9.62) | 0.03 (−0.03 to 0.08) |
| Quartile 2 | 5/80 (6.3) | 7/99 (7.1) | 0.88 (0.29 to 2.68) | −0.01 (−0.08 to 0.07) |
| Quartile 3 | 12/88 (13.6) | 17/90 (18.9) | 0.72 (0.37 to 1.42) | −0.05 (−0.16 to 0.06) |
| Quartile 4 | 21/91 (23.1) | 20/90 (22.2) | 1.04 (0.61 to 1.78) | 0.01 (−0.11 to 0.13) |
| Overall | 43/358 (12.0) | 46/359 (12.8) | 0.94 (0.64 to 1.38) | −0.01 (−0.06 to 0.04) |
Abbreviation: NDI, neurodevelopmental impairment.